Search clinical trials for: Dasatinib Placebo

Total 55119 results

Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Lymphoma | Unspecified Adult Solid Tumor, Protocol Specific

United States
Bristol-Myers Squibb

Active, not recruiting

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

Leukemia

France, India, United States, Canada, Spain, Italy, Mexico, South Africa, United Kingdom, Korea, Republic of, Russian Federation, Australia, Argentina, Germany, Brazil, Netherlands, Romania, Singapore
M.D. Anderson Cancer Center
Bristol-Myers Squibb; AstraZeneca

Terminated

Personalized Treatment Selection for Metastatic Breast Cancer

Breast Cancer

United States
Medstar Health Research Institute
Bristol-Myers Squibb

Completed

Solid Tumors Using Ixabepilone and Dasatinib

Solid Tumor

United States
Bristol-Myers Squibb

Terminated

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Leukemia

France, United States, Spain, Poland, Finland, Argentina, Canada, Belgium
Bristol-Myers Squibb

Terminated

Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Leukemia, Myeloid, Chronic

Sweden, United Kingdom, Russian Federation, France, Germany, Belgium, Portugal, Finland, Norway, Spain, Italy
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

Recurrent Salivary Gland Carcinoma | Salivary Gland Adenoid Cystic Carcinoma | Stage IV Major Salivary Gland Cancer AJCC v7 | Malignant Salivary Gland Neoplasm

United States, Canada
Peking University

Not yet recruiting

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Esophageal Squamous Cell Carcinoma

China
H. Lee Moffitt Cancer Center and Research Institute
Boehringer Ingelheim

Recruiting

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Squamous Cell Carcinoma

United States
Peking Union Medical College Hospital

Recruiting

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

Radioactive Iodine-refractory Differentiated Thyroid Cancer

China
Sun Yat-sen University

Not yet recruiting

Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Boehringer Ingelheim

Completed

A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

Squamous Non-small Cell Lung Cancer

United States
Beijing Friendship Hospital

Unknown

Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer

Gastric Cancer

China
Peking University People's Hospital
Peking University Shougang Hospital; Peking University International Hospital

Completed

Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use

Efficacy | Toxicity

China
Guangxi Medical University

Not yet recruiting

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

China
Fudan University

Not yet recruiting

A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer

HR+/HER2-breast Cancer
Hebei Medical University

Unknown

A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction

Gastroesophageal Junction Adenocarcinoma

China
Novartis Pharmaceuticals

Terminated

Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China

Neoplasms, Breast

Hong Kong, China
Puma Biotechnology, Inc.

Completed

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)

HER2+ Metastatic Breast Cancer (MBC)

United States, Canada, Spain, Singapore, Korea, Republic of, Taiwan, United Kingdom, Israel, Australia, Japan, Hong Kong, Finland, Ireland, Italy, France, Portugal, Germany, Sweden, Belgium, Brazil, Czechia, Switzerland, Argentina, Au... and more
Georgetown University
GlaxoSmithKline

Terminated

Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

Pancreas Cancer

United States
National Cancer Institute (NCI)

Completed

Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Adult Primary Hepatocellular...

United States
Jules Bordet Institute
GlaxoSmithKline; Schering-Plough

Completed

Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer (LAPTEM)

Metastatic Breast Cancer | Brain Metastases | HER2 Positive

Belgium
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

HER2 Positive Metastatic Breast Cancer

China
Centre Georges Francois Leclerc
Sanofi; GlaxoSmithKline

Completed

Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer (LapDoc)

Metastatic Breast Cancer

France
Centre Francois Baclesse
GlaxoSmithKline; Centre d'Etudes et de Recherche pour l'Intensification du...

Terminated

Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer (TOPO-LAPA)

Cancer | Chemotherapy | Relapse | Ovarian

France
Peking University Cancer Hospital & Institute
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline; Genentech, Inc.; Susan G. Komen Breast Cancer Foundation

Completed

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Breast Neoplasms

United States
Novartis Pharmaceuticals

Completed

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

Metastases, Brain

Spain, Hungary, Poland, Germany, Italy, Russian Federation, Sweden, United Kingdom, Thailand, United States, Belgium, France, Greece, Denmark
Ascentage Pharma Group Inc.
HealthQuest Pharma Inc.

Active, not recruiting

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Chronic Myeloid Leukemia, Chronic Phase

China
Medical College of Wisconsin
Memorial Sloan Kettering Cancer Center; Dana-Farber Cancer Institute; University... and other collaborators

Completed

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

Leukemia, Myeloid, Chronic

United States
LanZhou University
Beijing Health Alliance Charitable Foundation

Recruiting

Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Mycosis Fungoides | Multiple

United States
National University Hospital, Singapore

Recruiting

Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

NSCLC

Singapore
Sixth Affiliated Hospital, Sun Yat-sen University

Not yet recruiting

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma

China
Fudan University

Recruiting

Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

Carcinosarcoma | Sarcomatoid Carcinoma | PD-1 Immunotherapy | VEGFR-TKI

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence

China
Beijing Friendship Hospital

Completed

Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer

Gastric Cancer
Boehringer Ingelheim

Completed

ADAM-Afatinib Diarrhea Assessment and Management

Carcinoma, Non-Small-Cell Lung

United States
Shanghai Zhongshan Hospital

Unknown

A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer

Gastric Carcinoma

China
National Cancer Institute (NCI)

Completed

Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Adult Primary Hepatocellular...

United States
Johns Hopkins University
Medical University of South Carolina; Children's Hospital of Philadelphia; Washington... and other collaborators

Completed

Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease (HUPrevent)

Stroke | Sickle Cell Disease

United States
The First Affiliated Hospital of Kunming Medical...

Unknown

Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma

Lung Cancer
National Cancer Institute (NCI)
NRG Oncology; Radiation Therapy Oncology Group

Completed

Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Neoplasm

United States, Canada, Saudi Arabia
Shenzhen Second People's Hospital

Recruiting

The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients

Chronic Myeloid Leukemia in Chronic Phase

China
University of California, Irvine
Bristol-Myers Squibb

Completed

Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate Cancer

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma

Melanoma

United States
Bristol-Myers Squibb

Completed

Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study

Leukemia
Bristol-Myers Squibb

Terminated

A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

Leukemia

United States

Search clinical trials for: Dasatinib Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations